Cardiology
Feature
Survey: Hydroxychloroquine use fairly common in COVID-19
From the Journals
Consensus recommendations on AMI management during COVID-19
The ACC, ACEP, and SCAI recommend a systematic approach for the care of patients with an acute myocardial infarction during the COVID-19 pandemic...
News from the FDA/CDC
FDA grants Breakthrough Therapy status to sotatercept for PAH treatment
In preclinical research, this investigational drug “reversed pulmonary vessel muscularization and improved indicators of right heart failure.”
Latest News
Seniors with COVID-19 show unusual symptoms, doctors say
The age group most at risk of severe complications may not have fever, insistent cough, or shortness of breath.
Latest News
COVID-19 linked to large vessel stroke in young adults
The virus appears to cause disease through a process of blood clotting, according to an expert.
News
FDA reiterates hydroxychloroquine limitations for COVID-19
An FDA Safety Communication restates that hydroxychloroquine and chloroquine are only for hospitalized COVID-19 patients who can’t enter a trial...
News
COVID-19: What are the major cardiovascular issues?
COVID myocarditis can mimic acute MI or stress cardiomyopathy and will present diagnostic and therapeutic challenges.
From the Journals
Angiotensin drugs and COVID-19: More reassuring data
From the Journals
Hydroxychloroquine ineffective for COVID-19, VA study suggests
The retrospective study, which included
From the Journals
Signature STEMI sign may be less diagnostic in the COVID-19 age
From the Journals
ACEI/ARBs linked with survival in hypertensive, Chinese COVID-19 patients